Thera-SAbDab

DULIGOTUZUMAB

>   Structural Summary
TherapeuticDuligotuzumab
TargetERBB3/HER3
Heavy ChainEVQLVESGGGLVQPGGSLRLSCAASGFTLSGDWIHWVRQAPGKGLEWVGEISAAGGYTDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARESRVSFEAAMDYWGQGTLVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCRASQNIATDVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSEPEPYTFGQGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv Structure3p0v [Fvs: HL, IM], 3p0y [Fvs: HL], 3p11 [Fvs: HL]
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Duligotuzumab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 98.68%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 101 102 103 104 105 106 107 108 109 110 111 112 113
duligotuzumab E V Q L V E S G G G L V Q P G G S L R L S C A A S G F T L S G D W I H W V R Q A P G K G L E W V G E I S A A G G Y T D Y A D S V K G R F T I S A D T S K N T A Y L Q M N S L R A E D T A V Y Y C A R E S R V S F E A A M D Y W G Q G T L V T V S S
3p0v E V Q L V E S G G G L V Q P G G S L R L S C A A S G F T L S G D W I H W V R Q A P G K G L E W L G E I S A A G G Y T D Y A D S V K G R F T I S A D T S K N T A Y L Q M N S L R A E D T A V Y Y C A R E S R V S F E A A M D Y W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
duligotuzumab D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q N I A T D V A W Y Q Q K P G K A P K L L I Y S A S F L Y S G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C Q Q S E P E P Y T F G Q G T K V E I K
3p0v D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q D L A T D V A W Y Q Q K P G K A P K L L I Y S A S F L Y S G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C Q Q S E P E P Y T F G Q G T K V E I K
Sequence identity: 98.68%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 101 102 103 104 105 106 107 108 109 110 111 112 113
duligotuzumab E V Q L V E S G G G L V Q P G G S L R L S C A A S G F T L S G D W I H W V R Q A P G K G L E W V G E I S A A G G Y T D Y A D S V K G R F T I S A D T S K N T A Y L Q M N S L R A E D T A V Y Y C A R E S R V S F E A A M D Y W G Q G T L V T V S S
3p0y E V Q L V E S G G G L V Q P G G S L R L S C A A S G F T L S G D W I H W V R Q A P G K G L E W L G E I S A A G G Y T D Y A D S V K G R F T I S A D T S K N T A Y L Q M N S L R A E D T A V Y Y C A R E S R V S F E A A M D Y W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
duligotuzumab D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q N I A T D V A W Y Q Q K P G K A P K L L I Y S A S F L Y S G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C Q Q S E P E P Y T F G Q G T K V E I K
3p0y D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q D L A T D V A W Y Q Q K P G K A P K L L I Y S A S F L Y S G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C Q Q S E P E P Y T F G Q G T K V E I K
Sequence identity: 98.68%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 101 102 103 104 105 106 107 108 109 110 111 112 113
duligotuzumab E V Q L V E S G G G L V Q P G G S L R L S C A A S G F T L S G D W I H W V R Q A P G K G L E W V G E I S A A G G Y T D Y A D S V K G R F T I S A D T S K N T A Y L Q M N S L R A E D T A V Y Y C A R E S R V S F E A A M D Y W G Q G T L V T V S S
3p11 E V Q L V E S G G G L V Q P G G S L R L S C A A S G F T L S G D W I H W V R Q A P G K G L E W L G E I S A A G G Y T D Y A D S V K G R F T I S A D T S K N T A Y L Q M N S L R A E D T A V Y Y C A R E S R V S F E A A M D Y W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
duligotuzumab D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q N I A T D V A W Y Q Q K P G K A P K L L I Y S A S F L Y S G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C Q Q S E P E P Y T F G Q G T K V E I K
3p11 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q D L A T D V A W Y Q Q K P G K A P K L L I Y S A S F L Y S G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C Q Q S E P E P Y T F G Q G T K V E I K
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (Aug '24)Phase-II
Estimated Status (Aug '24)Discontinued
Recorded Developmental Technology
INN Year Proposed2012
INN Year Recommended2014
Companies InvolvedGenentech, Roche
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedSolid tumours, Colorectal cancer, Head and neck cancer
NotesDuligotuzumab is the new name for Duligotumab (PL110)

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy